couter

LOBE.CNLobe Sciences Ltd.

Health CarePharmaceuticals
Oct 6, 2026 — L-130 Clinical Pipeline Update
Chart by TradingView

The schedule

  • Tue6Oct

    Update on L-130 clinical progression and neurological pipeline momentum. Resolving between a jump to $0.10 or a drop to $0.05.

  • Wed25Nov

    FY 2026 Earnings release focusing on cash reserves against the $0.06 to $0.12 outcome band.

  • Fri15Jan

    High probability of a dilutive capital raise to sustain operations, evaluating a $0.08 vs $0.04 profile.

  • Thu18Feb

    FQ1 2027 Earnings announcement detailing post-dilution runway, framing a $0.06 target against a $0.03 fallback.

  • Tue20Apr

    FDA regulatory pathway update or Phase 2 trial initiation for L-130, testing a $0.07 upside vs $0.02 downside.

  • Thu27May

    FQ2 2027 Earnings update on R&D expenditure and trial enrollment, targeting $0.10 or falling to $0.05.